Our Mission Statement
Our core mission is to unlock the full economic and therapeutic potential of the Soluble Film dosage form for healthcare applications.
NTFP values execution and efficiency which require access to top talent, facilities and operating costs that create value for our partners. We are proud to have selected North Carolina as the location for NTFP. NTFP operates at two North Carolina locations; Greensboro and Wilmington.
Joseph Fuisz and Dr. Madhu Hariharan, pioneers in OSF with deep industry backgrounds, co-founded NTFP with the mission to broaden the applicability of OSF by using DepoFilm™ technology. NTFP’s DepoFilm™ version 2.0 OSF technology circumvents many of the drawbacks that have historically prevented widespread adoption of OSF.
Our management team and board is composed of a group that essentially created the modern pharma OSF industry. Joseph and Richard Fuisz helped start the soluble film drug delivery sector, inventing the largest patent portfolio for pharmaceutical OSF by solution-casting. Madhu Hariharan is a pharma R&D executive and drug delivery expert who has worked in the generic, specialty and ethical pharmaceutical industry for over 25 years. Dr. Yousry Sayed, is the founder and CEO of Quality Chemical Laboratories, one of the leading pharmaceutical CDMOs in the US.
Joseph Fuisz, JD
Mr. Fuisz serves as our Chief Executive Officer. Mr. Fuisz has worked in the pharmaceutical industry for eighteen years. He is a named inventor on over thirty issued US patents, including the largest patent estate related to wet-cast films. Mr. Fuisz co-founded the world’s largest wet-cast thin film company and served as its Senior Vice President for Business Development. Subsequently, Mr. Fuisz co-founded a company acquired by a leading global consumer products company based on Fuisz-patented extruded sheet technology. Mr. Fuisz also served as CEO of a vaginal drug delivery company acquired by a global pharmaceutical company. Joseph Fuisz has a BA from Yale University and a JD from the Columbia University School of Law. He is a member of the bar in the State of New York and the District of Columbia, and a Slovene American.
Madhu Hariharan, PhD
Dr. Hariharan serves as both our Chief Operating Officer and Chief Scientific Officer. He is a pharmaceutical industry executive with diverse work experience in product development, regulatory filing, technical operations and commercial launch of Rx, generic and OTC pharmaceuticals and nutraceuticals. He has worked in the area of complex drug delivery systems for the majority of his 25 years in the pharmaceutical industry, serving in a variety of technical leadership positions at specialty pharma companies as well as ethical and generic pharma companies. His expertise is in the area of pre-formulation, formulation, technical operations, regulatory filings and strategy for soluble films, implants and other complex dosage forms. He is the author of several scientific publications and is an inventor on a number of patents in the area of drug delivery. Madhu Hariharan has a Bachelor’s degree in Pharmacy and a Ph.D. in Pharmaceutics.
Board of Directors
Richard C. Fuisz, MD
Richard Fuisz M.D. has been a principal architect of two novel dosage forms: orally disintegrating tablets, and orally soluble films. He founded and served as CEO of two public healthcare companies, both acquired. He is an inventor on over 130+ issued United States patents, principally relating to drug delivery but also to diverse fields including electronic mail, computer databases, cipher systems, and others. Dr. Fuisz’s inventions include the largest patent estate relating to wet-cast films. Dr. Fuisz is a graduate of Georgetown College and Georgetown Medical School, and a Slovene American.
Yousry Sayed, PhD
Dr. Sayed was a longtime faculty member in the chemistry and biochemistry department, a student mentor and the former director of the General College, now known as University College of the University of North Carolina, Wilmington. Dr. Yousry Sayed is the founder and CEO of Quality Chemical Laboratories (QCL), one of the leading pharmaceutical CDMOs in the US. QCL is a partner and lead investor in NTFP.
Giovanni Pauletti, PhD
Dr Pauletti is currently the Gustavus and Henry Pfeiffer Endowed Professor and Chair of the Department of Pharmaceutical and Administrative Sciences at the St. Louis College of Pharmacy. Dr Pauletti has dedicated his academic research career to improve safety and therapeutic efficacy of drug interventions in patients by applying innovative drug delivery technologies.
Andrew Finn, Pharm.D
Dr Finn has 35 years of experience in pharmaceutical and clinical development experience. He has served in a variety of senior scientific roles at Glaxo, Solvay, Pozen, BDSI and AviorBio. He has numerous publications and patents in the area of clinical research and drug delivery.